Linaclotide

Linaclotide is a synthetic 14-amino-acid peptide (a tetradecapeptide) structurally related to guanylin and uroguanylin, two naturally occurring intestinal peptide hormones that regulate fluid and electrolyte secretion by activating the guanylate cyclase-C (GC-C) receptor on the luminal surface of intestinal epithelial cells. Linaclotide's structure is cyclized through three disulfide bonds, bridging cysteine residues at positions 1-6, 2-10, and 5-13, a more complex multi-disulfide cyclization pattern than any other peptide profiled in this catalog.

At Verified Peptides, we want to highlight a genuinely distinctive pharmacokinetic feature of this compound relative to essentially every other peptide in this catalog: Linaclotide is administered as an oral capsule and is specifically engineered to achieve minimal systemic absorption, remaining largely confined to the intestinal lumen where it acts locally, and is reported as undetectable in the systemic circulation at therapeutic doses. This is the inverse of the typical peptide drug development challenge (achieving adequate absorption and bioavailability) discussed throughout this catalog's other profiles — for Linaclotide, the absence of systemic absorption is precisely the intended and clinically desirable pharmacokinetic property, since its therapeutic action is meant to occur locally within the gut rather than through any systemic hormonal effect.

Chemically, Linaclotide has molecular formula C59H79N15O21S6, molecular weight approximately 1526.8 g/mol, CAS number 851199-59-2, PubChem CID 16158208. It was FDA-approved in 2012 (as Linzess, developed by Ironwood Pharmaceuticals) for irritable bowel syndrome with constipation (IBS-C) in adults and, later, in pediatric patients aged 7 and older, and for chronic idiopathic constipation in adults, with an indication expansion in June 2023 adding functional constipation treatment in pediatric patients aged 2 and older.

Linaclotide's three disulfide bonds create a compact, rigid cyclic structure believed necessary for stable GC-C receptor binding, and this triple-cyclization pattern is considerably more complex than the single disulfide bridge used in Octreotide (also built on this site), reflecting the specific structural requirements of the guanylin/uroguanylin receptor family compared to the somatostatin receptor family. A related endogenous peptide family member, Plecanatide (also built elsewhere in this catalog), uses a similar but distinct cyclization and sequence approach to activate the same GC-C receptor.

At Verified Peptides, we think Linaclotide has a substantial, rigorously documented clinical evidence base directly supporting its FDA-approved indications. The key citation is Quigley et al. (2013, Alimentary Pharmacology & Therapeutics, PMID 23116208, volume 37, issue 1, pages 49-61), a prespecified analysis of two Phase III, randomized, double-blind, placebo-controlled, multicenter trials using European Medicines Agency-specified co-primary endpoints. Using the 12-week abdominal pain/discomfort responder endpoint (defined as at least a 30% reduction in mean abdominal pain/discomfort score, without worsening, for at least 6 of the 12 weeks), linaclotide-treated patients showed significantly higher responder rates than placebo in both trials (54.8% versus 41.8% in one trial, 54.1% versus 38.5% in the other, both p less than 0.001) — real, statistically robust, clinically meaningful evidence directly supporting the FDA approval.

We want to note that Linaclotide's minimal systemic absorption is itself supported by pharmacokinetic study data showing the compound is essentially undetectable in the bloodstream at therapeutic oral doses, a finding relevant to interpreting its safety profile, since a drug that does not enter systemic circulation in meaningful concentrations is mechanistically less likely to produce the kinds of systemic adverse effects associated with peptides that must achieve substantial bloodstream exposure to reach their target tissue. The most commonly reported adverse effect in clinical trials was diarrhea, a direct extension of the drug's intended local secretory mechanism rather than an off-target systemic effect.

At Verified Peptides, we sell research-grade Linaclotide exclusively for laboratory research, and we think this compound's local-action, minimal-absorption pharmacokinetic profile makes it a genuinely useful contrast point for researchers accustomed to thinking about peptide drug development primarily in terms of maximizing systemic bioavailability, as is the goal for most other peptides in this catalog.

We also want to note that Linaclotide's clinical development program specifically addressed the European Medicines Agency's more stringent, co-primary-endpoint requirements for IBS-C drugs, which mandate simultaneous demonstration of benefit on both bowel-symptom measures and abdominal pain/discomfort measures rather than either domain alone. This EMA-specific endpoint structure reflects a broader regulatory recognition that IBS-C is fundamentally a multi-symptom disorder, and that a therapy demonstrating benefit on stool frequency alone, without addressing pain, would not adequately address the condition's full clinical burden — a regulatory-science nuance we think is worth understanding when evaluating any IBS-C therapy's clinical trial design, not just Linaclotide's specifically.

Guanylin and uroguanylin, the endogenous hormones Linaclotide is modeled on, are part of a broader family of peptide hormones that also includes the heat-stable enterotoxins produced by certain pathogenic strains of Escherichia coli, which cause traveler's diarrhea by binding and activating the same GC-C receptor — meaning Linaclotide's therapeutic mechanism is, in a sense, a deliberately controlled and clinically beneficial pharmaceutical application of the same fundamental receptor pathway that certain bacterial toxins exploit to cause disease.

The development of Linaclotide and its structurally related successor compound, Plecanatide (also built elsewhere in this catalog), reflects a broader pattern of pharmaceutical development building directly on endogenous guanylin/uroguanylin biology, with each compound representing a distinct specific engineering approach to achieving a stable, orally deliverable, locally acting GC-C agonist peptide.

Linaclotide's essentially complete lack of systemic absorption is itself an active area of ongoing pharmaceutical formulation research, since achieving reliable, reproducible non-absorption while still ensuring adequate local drug concentration and residence time within the intestinal lumen requires careful attention to the peptide's physicochemical properties, a formulation challenge distinct from (and in some ways more unusual than) the more commonly discussed challenge of maximizing absorption for peptide drugs intended for systemic effect.

Linaclotide's approval also reflects a broader shift in gastroenterology drug development toward mechanistically targeted receptor agonists and antagonists, moving away from older, less mechanistically specific approaches to chronic constipation management such as osmotic or stimulant laxatives, which act through more general physical or non-receptor-specific mechanisms rather than a defined molecular target.

At Verified Peptides, we require independent third-party HPLC purity testing and mass spectrometry identity confirmation for every batch of research-grade Linaclotide we offer, with a Certificate of Analysis (COA) available for each lot. Given Linaclotide's complex triple-disulfide-bonded cyclic structure, correct formation of all three disulfide bridges (rather than partial or incorrect cyclization patterns) should be confirmed as part of identity testing, since incomplete or misfolded cyclization would represent a structurally distinct, likely non-functional molecule.

We source exclusively from manufacturers operating under Good Manufacturing Practice (GMP)-aligned quality systems, and every lot is independently verified rather than accepted solely on a supplier's internal documentation. Researchers should always request and review the specific COA for the lot they receive, confirming purity percentage and molecular identity before use in any experimental protocol, including mass spectrometry verification consistent with the fully oxidized, triple-disulfide-bonded product rather than a partially reduced intermediate.

Lyophilized Linaclotide is stable when stored at -20°C, protected from light and moisture. At Verified Peptides, we ship lyophilized peptide with appropriate cold-chain packaging to preserve stability in transit.

Once reconstituted, solution should be stored refrigerated at 2–8°C and used within the timeframe indicated on the product's documentation, avoiding repeated freeze-thaw cycles. As a peptide with three disulfide bonds, Linaclotide may be particularly sensitive to reducing conditions that could disrupt its cyclic structure, so researchers should follow lot-specific handling guidance to preserve structural integrity, avoiding exposure to strong reducing agents that could cleave one or more of the three disulfide bridges and disrupt the peptide's folded conformation.